Kahan Biotech Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 21-06-2024
- Paid Up Capital ₹ 1.50 M
as on 21-06-2024
- Company Age 15 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 8.00 M
as on 21-06-2024
- Revenue -10.38%
(FY 2022)
- Profit 35.22%
(FY 2022)
- Ebitda -252.48%
(FY 2022)
- Net Worth -11.88%
(FY 2022)
- Total Assets 1.12%
(FY 2022)
About Kahan Biotech
The Company is engaged in the Life Science Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company has closed loans amounting to ₹8.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Sejal Mehta, Priyal Mehta, Lalitaben Mehta, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24239GJ2009PTC057894
- Company No.
057894
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Aug 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Kahan Biotech Private Limited offer?
Kahan Biotech Private Limited offers a wide range of products and services, including Ayurvedic & Herbal Extracts, Floral Extract, Plant Extracts, Spice Oil, Caraway Oil, Ayurvedic Medicine, Ayurvedic Cough & Cold Medicine, Herbal Extracts, Fresh Flowers, Plants & Trees, Garden Plant.
Who are the key members and board of directors at Kahan Biotech?
Board Members(5)
Financial Performance and Corporate Structure Insights of Kahan Biotech.
Kahan Biotech Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 10.38% decrease. The company also saw a substantial improvement in profitability, with a 35.22% increase in profit. The company's net worth observed a substantial decline by a decrease of 11.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kahan Biotech?
In 2021, Kahan Biotech had a promoter holding of 58.00% and a public holding of 42.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
1 year 4 months Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Ahmedabad Mercatile Co. Op. Bank Ltd. Creation Date: 17 Mar 2011 | ₹8.00 M | Satisfied |
How Many Employees Work at Kahan Biotech?
Unlock and access historical data on people associated with Kahan Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Nov 03, 2010, Kahan Biotech has raised a total of ₹ 1.5 M, with the most recent deal valued at ₹ 1.3 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
